ASH 2018 and Multiple Myeloma View overview page

Myeloma XI trial: increased progression-free survival

Charlotte Pawlyn

MM has a bright future: highlights from ASH

Promising combination of ixazomib, lenalidomide & dex in high-risk smoldering myeloma

Melflufen and dex with bortezomib/daratumumab for myeloma: OP-104 study

Predicting IMiD sensitivity in myeloma

High economic burden for progressive multiple myeloma: considering costs

Isatuximab plus VRd for newly diagnosed transplant-ineligible myeloma

High treatment attrition in newly diagnosed multiple myeloma patients

Multiple myeloma musings: highlights from 2018 data

Current challenges for multiple myeloma therapy: 2, 3, 4-drug combinations

Pivotal STORM study: selinexor for penta-refractory multiple myeloma

Mohamad Mohty’s myeloma highlights from ASH 2018

An exciting era for CAR T-cell therapy

Hot topic: Geriatric Assessment in Hematology (GAH) scale

Understanding myeloma disease dissemination: are CTCs responsible?

A step towards next-generation immune monitoring in multiple myeloma?

1
2
3
Next